Repligen to acquire Metenova for cash and equity; adds magnetic mixing technology

REPLIGEN CORP

Metenova projected FY2023 revenue $24-25M; ~50 employees; magnetic mixers for bioprocess.
Expected close Q4 2023; funded with ~$604M cash on hand (cash + equity consideration).
Metenova expected to contribute $5M revenue in Q4 2023, $25-27M in 2024, 20-25% growth in 2025.
Deal projected accretive to adjusted gross/operating margins in 2024 and adjusted EPS in 2025.
Adds single-use MixOne platform; complements Repligen's fluid management and FlexBiosys bag business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.